Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
27.72M
Cash
19.14M
Avg Qtr Burn
-4.923M
Short % of Float
0.64%
Insider Ownership
20.34%
Institutional Own.
54.29%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Auxora™ Details Acute Pancreatitis | Phase 2b Data readout | |
Auxora™ Details Asparaginase-induced pancreatic toxicity | Phase 2 Data readout | |
Auxora™ Details Acute Kidney Injury, Kidney disease | Phase 2 Data readout | |
GB-102 (Pan-VEGF inhibitor) Details Eye disease , Wet age-related macular degeneration , Age-related macular degeneration | Failed Discontinued | |
GB-102 (Pan-VEGF inhibitor) Details Diabetes, Eye disease , Diabetic macular edema | Failed Discontinued |